Patents Assigned to Portola Pharmaceuticals, Inc.
-
Publication number: 20210052582Abstract: Provided herein are methods of using Syk inhibitors, such as a selective Syk inhibitor, Compound 1 or a pharmaceutically acceptable salt thereof, in treating allergic and/or inflammatory diseases or conditions of the eye. Also provided is pharmaceutical compositions, in particular eyedrop ophthalmic compositions, comprising Compound 1 or a pharmaceutically acceptable salt thereof, useful in the methods.Type: ApplicationFiled: March 8, 2019Publication date: February 25, 2021Applicants: Portola Pharmaceuticals, Inc., ORA, Inc.Inventors: Anjali PANDEY, Matthew CHAPIN, Harold PATTERSON, Yung Yueh HSU, Mark ABELSON
-
Patent number: 10851087Abstract: The present disclosure provides processes for the preparation of cerdulatinib, which is of formula I: or a salt thereof. The disclosure also provides intermediates and processes for the preparation of the intermediates useful in the preparation of cerdulatinib or a salt thereof.Type: GrantFiled: May 3, 2019Date of Patent: December 1, 2020Assignee: Portola Pharmaceuticals, Inc.Inventors: Anjali Pandey, Arvinder Sran, Ying Chen, Daniele Poggiali, Tiziano Fumagalli
-
Patent number: 10765726Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: GrantFiled: December 6, 2017Date of Patent: September 8, 2020Assignee: Portola Pharmaceuticals, Inc.Inventors: Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
-
Patent number: 10736895Abstract: Disclosed herein are methods and uses of cerdulatinib for treating diseases or conditions, including hematological cancers, and combinations of cerdulatinib for treating such diseases or conditions.Type: GrantFiled: December 2, 2016Date of Patent: August 11, 2020Assignee: Portola Pharmaceuticals, Inc.Inventors: Gregory Coffey, Jiajia Feng, Andrew Steele
-
Patent number: 10675335Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: GrantFiled: June 8, 2016Date of Patent: June 9, 2020Assignee: Portola Pharmaceuticals, Inc.Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
-
Patent number: 10604748Abstract: The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.Type: GrantFiled: June 19, 2017Date of Patent: March 31, 2020Assignee: Portola Pharmaceuticals, Inc.Inventors: Mark Karbarz, Pamela B. Conley, Genmin Lu
-
Patent number: 10533001Abstract: The present invention is directed to topical pharmaceutical compositions of Formula (If) or pharmaceutically acceptable salt thereof, which act as inhibitors of syk and/or JAK kinase activity. The described topical pharmaceutical compositions are useful in preventing or treating a number of conditions mediated at least in part by syk and/or JAK kinase activity.Type: GrantFiled: November 30, 2017Date of Patent: January 14, 2020Assignee: PORTOLA PHARMACEUTICALS, INC.Inventors: Shawn M. Bauer, Zhaozhong J. Jia, Mukund Mehrotra, Yonghong Song, Qing Xu, Wolin Huang, Chandrasekar Venkataramani, Jack W. Rose, Anjali Pandey
-
Patent number: 10190111Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: GrantFiled: February 16, 2017Date of Patent: January 29, 2019Assignee: Portola Pharmaceuticals, Inc.Inventors: Uma Sinha, Genmin Lu, Pamela B. Conley
-
Publication number: 20180353506Abstract: Disclosed herein are methods and uses of cerdulatinib for treating diseases or conditions, including hematological cancers, and combinations of cerdulatinib for treating such diseases or conditions.Type: ApplicationFiled: December 2, 2016Publication date: December 13, 2018Applicant: Portola Pharmaceuticals, Inc.Inventors: Gregory Coffey, Jiajia Feng, Andrew Steele
-
Patent number: 9902688Abstract: The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.Type: GrantFiled: May 10, 2016Date of Patent: February 27, 2018Assignee: PORTOLA PHARMACEUTICALS, INC.Inventors: Zhaozhong J. Jia, Yonghong Song, Qing Xu, Brian Kane, Shawn M. Bauer, Anjali Pandey
-
Patent number: 9868729Abstract: Provided are methods of treating inflammatory disorders, autoimmune disorders, or a hematological malignancies using compounds of formula I and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof. Such disorders and conditions include leukemia and Non Hodgkin's Lymphoma.Type: GrantFiled: December 5, 2014Date of Patent: January 16, 2018Assignee: PORTOLA PHARMACEUTICALS, INC.Inventors: Shawn M. Bauer, Anjali Pandey
-
Publication number: 20170369862Abstract: The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.Type: ApplicationFiled: June 19, 2017Publication date: December 28, 2017Applicant: Portola Pharmaceuticals, Inc.Inventors: Mark Karbarz, Pamela B. Conley, Genmin Lu
-
Patent number: 9834548Abstract: In one aspect, the invention provides a compound according to formula I, as well as tautomers, pharmaceutically acceptable salts, and hydrates thereof. Pharmaceutical compositions, methods of inhibiting Janus kinases (JAKs), and methods for treating a condition or disorder mediated at least in part by JAK kinase activity are also described.Type: GrantFiled: February 12, 2015Date of Patent: December 5, 2017Assignee: Portola Pharmaceuticals, Inc.Inventors: Qing Xu, Yonghong Song, Anjali Pandey
-
Patent number: 9676756Abstract: Provided are substituted pyrimidinyl compounds for inhibition of JAK and/or Syk kinase, pharmaceutical compositions thereof, methods for inhibiting JAK and/or Syk kinase activity, and methods for treating conditions mediated at least in part by JAK and/or Syk kinase activity.Type: GrantFiled: October 8, 2013Date of Patent: June 13, 2017Assignee: PORTOLA PHARMACEUTICALS, INC.Inventors: Shawn M. Bauer, Zhaozhong J. Jia, Yonghong Song, Anjali Pandey
-
Patent number: 9644195Abstract: Disclosed herein are compounds, compositions, methods and kits for purifying a serine protease and serine proteases purified with the compounds, compositions and methods.Type: GrantFiled: May 27, 2015Date of Patent: May 9, 2017Assignee: Portola Pharmaceuticals, Inc.Inventors: Anjali Pandey, Jack W. Rose
-
Patent number: 9587233Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: GrantFiled: July 2, 2015Date of Patent: March 7, 2017Assignee: Portola Pharmaceuticals, Inc.Inventors: Uma Sinha, Genmin Lu, Pamela B. Conley
-
Patent number: 9579320Abstract: The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.Type: GrantFiled: December 19, 2014Date of Patent: February 28, 2017Assignee: Portola Pharmaceuticals, Inc.Inventors: Zhaozhong J. Jia, Chandrasekar Venkataramani, Wolin Huang, Mukund Mehrotra, Yonghong Song, Qing Xu, Shawn M. Bauer, Jack W. Rose, Brian Kane, Anjali Pandey
-
Patent number: 9533986Abstract: Provided are bicyclic dihydropyridone compounds for inhibiting of JAK/Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting JAK/Syk kinase activity, and methods for treating conditions mediated at least in part by JAK/Syk kinase activity.Type: GrantFiled: September 27, 2013Date of Patent: January 3, 2017Assignee: PORTOLA PHARMACEUTICALS, INC.Inventors: Anjali Pandey, Yonghong Song, Qing Xu
-
Patent number: 9469654Abstract: Provided are bicyclic oxa-lactam compounds of formula I: and pharmaceutically acceptable salts thereof which are inhibitors of JAK/Syk kinase. The present disclosure is also directed to intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting JAK/Syk kinase activity, and methods for treating conditions mediated at least in part by JAK/Syk kinase activity.Type: GrantFiled: September 27, 2013Date of Patent: October 18, 2016Assignee: PORTOLA PHARMACEUTICALS, INC.Inventors: Anjali Pandey, Yonghong Song, Qing Xu
-
Publication number: 20160237420Abstract: The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, a stabilizer, and a crystalline component, wherein the formulation does not collapse during lyophilization.Type: ApplicationFiled: April 22, 2016Publication date: August 18, 2016Applicant: Portola Pharmaceuticals, Inc.Inventors: Juan Wang, Gregory A. Sacha, Phuong M. Nguyen